275 related articles for article (PubMed ID: 33038451)
1. Protein kinases as targets for developing anticancer agents from marine organisms.
Qiao G; Bi K; Liu J; Cao S; Liu M; Pešić M; Lin X
Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129759. PubMed ID: 33038451
[TBL] [Abstract][Full Text] [Related]
2. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
[TBL] [Abstract][Full Text] [Related]
3. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
4. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
5. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
6. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
7. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
Wu P; Hu YZ
Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
[TBL] [Abstract][Full Text] [Related]
8. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
9. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
10. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
11. Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents.
Sun H; Wang Z; Yakisich JS
Anticancer Agents Med Chem; 2013 Sep; 13(7):1048-56. PubMed ID: 23293890
[TBL] [Abstract][Full Text] [Related]
12. Novel cancer chemotherapy hits by molecular topology: dual Akt and Beta-catenin inhibitors.
Zanni R; Galvez-Llompart M; Morell C; Rodríguez-Henche N; Díaz-Laviada I; Recio-Iglesias MC; Garcia-Domenech R; Galvez J
PLoS One; 2015; 10(4):e0124244. PubMed ID: 25910265
[TBL] [Abstract][Full Text] [Related]
13. Recent Progress of Marine Polypeptides as Anticancer Agents.
Zheng L; Xu Y; Lin X; Yuan Z; Liu M; Cao S; Zhang F; Linhardt RJ
Recent Pat Anticancer Drug Discov; 2018; 13(4):445-454. PubMed ID: 29708076
[TBL] [Abstract][Full Text] [Related]
14. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity.
Ibáñez E; Agliano A; Prior C; Nguewa P; Redrado M; González-Zubeldia I; Plano D; Palop JA; Sanmartín C; Calvo A
Curr Med Chem; 2012; 19(18):3031-43. PubMed ID: 22455594
[TBL] [Abstract][Full Text] [Related]
15. Probing the PI3K/Akt/mTor pathway using
Phyu SM; Tseng CC; Fleming IN; Smith TA
Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
[TBL] [Abstract][Full Text] [Related]
16. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
[TBL] [Abstract][Full Text] [Related]
18. Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes.
Liu L; Zhao X; Pierre SV; Askari A
Am J Physiol Cell Physiol; 2007 Nov; 293(5):C1489-97. PubMed ID: 17728397
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.
Sathe A; Nawroth R
Methods Mol Biol; 2018; 1655():335-350. PubMed ID: 28889395
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
